HLA class II histocompatibility antigen DRB1-15 beta chain (HLA-DRB1*15)

The HLA class II histocompatibility antigen DRB1-15 beta chain is a polymorphic protein that forms part of the Major Histocompatibility Complex (MHC) class II heterodimer, essential for the adaptive immune system [2, 3]. It functions by binding and presenting exogenous peptide fragments to CD4+ T-cell receptors, thereby triggering immune responses against pathogens [3, 5]. This specific variant, particularly the HLA-DRB1*15:01 allele, is recognized as the strongest genetic risk factor for multiple sclerosis (MS), where it is implicated in the presentation of myelin self-antigens to autoreactive T cells [8, 11]. It is also associated with other autoimmune disorders such as Goodpasture syndrome and systemic lupus erythematosus, as well as a significantly increased risk of drug-induced liver injury (DILI) from agents like amoxicillin-clavulanate [1, 4]. Therapeutic interventions targeting this molecule include glatiramer acetate, which acts as a competitive binder, and investigational agents like apolizumab and PV-267 designed to inhibit its antigen-presenting capacity [7, 11, 13]. Understanding its role is crucial for developing allele-specific immunotherapies that aim to suppress autoimmunity without compromising global immune function [11].

Other names

HLA-DRB1*15:01HLA-DR15MHC class II antigen DRB1*15DR2bDRB1*15

Competitive inhibition of antigen binding, HLA-DR beta chain inhibition, and antigen presentation modulation.